Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
暂无分享,去创建一个
M. Ostland | P. Jänne | Bruce E. Johnson | R. Herbst | S. Seshagiri | V. Miller | David H. Johnson | K. Hillan | L. Amler | D. Eberhard | A. Goddard | S. Heldens | William L. Ince | T. Januario | P. Klein | D. Ramies | Dragan Sebisanovic | J. Stinson | Yu Zhang | B. Johnson | David H. Johnson | Jeremy Stinson | Sherry Heldens
[1] K. Sugimachi,et al. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.
[2] E. Mark,et al. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. , 1999, Journal of the National Cancer Institute.
[3] M. Rooney,et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Muscat,et al. K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. , 1999, Carcinogenesis.
[5] D. Sidransky,et al. Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung , 2001, Cancer.
[6] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[7] F. Bray,et al. Cancer burden in the year 2000. The global picture. , 2001, European journal of cancer.
[8] J. Jett,et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] S. Piantadosi,et al. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. , 2001, Cancer research.
[10] K. Kinzler,et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.
[11] Michael Thomas,et al. Trimodality treatment in Stage III nonsmall cell lung carcinoma , 2002, Cancer.
[12] M. Vangel,et al. The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer. , 2002, Lung cancer.
[13] A. Sandler. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. , 2003, Oncology.
[14] Q. She,et al. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] Y. Yatabe,et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status. , 2003, Lung cancer.
[16] M. Sliwkowski,et al. Preclinical studies with Erlotinib (Tarceva). , 2003, Seminars in oncology.
[17] G. Mills,et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.
[18] D. M. Parkin,et al. Corrigendum to “Cancer burden in the year 2000. The global picture” [European Journal of Cancer,37(Suppl. 8) (2001) S4–S66] , 2003 .
[19] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Ardizzoni,et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. , 2003, European journal of cancer.
[21] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[22] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[23] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[24] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] P. Jänne,et al. Preliminary results from a phase II study of the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in patients > 70 years of age with previously untreated advanced non-small cell lung carcinoma , 2004 .
[27] J. Baselga. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] W. Evans. Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer. , 2004, Cancer treatment reviews.
[29] A. Bezjak,et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial , 2004 .
[30] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Rigas,et al. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.